206 related articles for article (PubMed ID: 35931640)
21. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
Bianchi A; Valentini F; Iuorio R; Poggi M; Baldelli R; Passeri M; Giampietro A; Tartaglione L; Chiloiro S; Appetecchia M; Gargiulo P; Fabbri A; Toscano V; Pontecorvi A; De Marinis L
J Exp Clin Cancer Res; 2013 Jun; 32(1):40. PubMed ID: 23799893
[TBL] [Abstract][Full Text] [Related]
23. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
24. New perspectives in the medical treatment of acromegaly.
Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
[TBL] [Abstract][Full Text] [Related]
25. [Epidemiology of acromegaly in Spain].
Sesmilo G
Endocrinol Nutr; 2013 Oct; 60(8):470-4. PubMed ID: 23246411
[TBL] [Abstract][Full Text] [Related]
26. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
27. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
[TBL] [Abstract][Full Text] [Related]
28. Pasireotide in the Personalized Treatment of Acromegaly.
Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
[TBL] [Abstract][Full Text] [Related]
29. Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal.
Yu N; Wang L; Yang H; Pan H; Duan L; Zhu H
J Clin Pharm Ther; 2022 Jun; 47(6):835-840. PubMed ID: 35167717
[TBL] [Abstract][Full Text] [Related]
30. Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
Mercado M; Abreu C; Vergara-López A; González-Virla B; Espinosa-de-Los-Monteros AL; Sosa-Eroza E; Cadena-Obando D; Cuevas-Ramos D; Portocarrero-Ortiz LA; Pérez-Reyes SP; Mercado-Cherem A; Ibarra-Salce R; Talavera JO
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32944780
[TBL] [Abstract][Full Text] [Related]
31. Management of endocrine disease: GH excess: diagnosis and medical therapy.
Andersen M
Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
[TBL] [Abstract][Full Text] [Related]
32. Modern approach to resistant acromegaly.
Giustina A; di Filippo L; Uygur MM; Frara S
Endocrine; 2023 May; 80(2):303-307. PubMed ID: 36790521
[TBL] [Abstract][Full Text] [Related]
33. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
35. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
36. Current therapy and drug pipeline for the treatment of patients with acromegaly.
Kumar SS; Ayuk J; Murray RD
Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
[TBL] [Abstract][Full Text] [Related]
37. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
38. [Optimization of the medical treatment for acromegaly].
Díez JJ; Iglesias P
Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
[TBL] [Abstract][Full Text] [Related]
39. Pegvisomant: new preparation. A last resort in acromegaly.
Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
[TBL] [Abstract][Full Text] [Related]
40. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
